Silicon Valley Philanthropist Shares Review of CDC Data: COVID-19 Vaccine Associated with 100X Deaths Compared to Influenzas

Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.

The following was produced by Steve Kirsch. TrialSite’s Op-ed exists to provide point of view and perspective, not necessarily the view of this media platform. But diversity of opinion and perspective during a crisis such as this is of utmost importance. Steve Kirsch, a drug development philanthropist, regular contributor to the TrialSite, and founder of the COVID-19 Early Treatment Fund (CETF), is actively funding research into generic repurposed drugs such as fluvoxamine that evidence efficacy targeting COVID-19. Kirsch, a trained engineer from Massachusetts Institute of Technology (MIT), made a fortune in Silicon Valley, inventing notable technologies such as the optimal mouse. The Silicon Valley entrepreneur turned drug development philanthropist now studies the novel COVID-19 vaccines, with a particular interest in ensuring that the public is sufficiently safe. He recently focused his attention on the Centers for Disease Control and Prevention (CDC) Vaccine Adverse Event Reporting System (VAERS), comparing and evaluating the past ten...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee